Osteomyelitis: Anti-Infective Grafts vs Biologic Allografts

Antibiotic-loaded bone graft substitutes, S53P4 bioactive glass, and biologic allografts for osteomyelitis — staging, protocol, when biologics win.

Published 2026-08-21 | Clinical education for wound care physicians, podiatrists, nurses, and wound-center medical directors
By Josh Fathi, Founder, NextGen Biologics
Reviewed by the NextGen Biologics clinical editorial team against cited sources
This content is informational and not medical advice; it is not a substitute for professional diagnosis or treatment.

Anti-Infective Biomaterials for Osteomyelitis: How New Bone Graft Technologies Compare to Debridement + Biologic Grafting Sequences

Osteomyelitis presents clinicians with two jobs at once: eradicate the bone infection, then restore bone that the infection destroyed. The traditional sequence separates those jobs — debridement and culture-directed antibiotics first, reconstruction later, often weeks to months apart. A growing class of anti-infective, regenerative biomaterials is designed to bring the two jobs together, offering local antimicrobial delivery, bone-filling capacity, and immune modulation in a single implant.

For wound-care teams that escalate to biologic grafting in complex lower-extremity cases, the practical question is: do these materials change the debridement + biologic sequence, and when does a biologic allograft remain the right call? This brief compares the emerging biomaterial categories against current staging practice and gives clinicians a framework for choosing.

The Current Sequence: Debridement, Dead-Space Control, Delayed Reconstruction

Standard management of chronic osteomyelitis begins with surgical resection of necrotic bone and soft tissue, followed by culture-directed systemic antibiotics. The Infectious Diseases Society of America's diabetic foot infection guideline anchors this approach: infection requires removal of dead bone, adequate drainage, and antibiotic therapy matched to culture results (Lipsky et al., 2012, PMID 22619242).

After resection, the surgeon is left with dead space that must be managed or the infection recurs. The classic solution is local antibiotic delivery — antibiotic-laden PMMA beads or spacers eluting high drug concentrations at the infection site while systemic therapy runs (Ford et al., 2017, PMID 28837368). PMMA is inert, however; it provides no bone regeneration and requires a second operation for removal.

Reconstruction is therefore typically staged. The induced membrane (Masquelet) technique exemplifies this: a PMMA spacer is placed at the first operation to create a vascularized membrane, then removed at a second stage and the defect grafted (Fung et al., 2020, PMID 33249891). Antibiotic duration is itself under scrutiny — a randomized noninferiority pilot in diabetic foot osteomyelitis found a 3-week course noninferior to 6 weeks when resection was adequate (Gariani et al., 2021, PMID 33242083) — but the two-stage surgical structure has been the default.

Biologic soft-tissue allografts — amniotic membrane and related HCT/Ps — have entered this sequence as a wound-closure layer, applied after infection control to a prepared bed to support epithelialization and modulate inflammation. They are not bone void fillers and carry no meaningful anti-infective payload; their role in osteomyelitis care is the soft-tissue envelope, not the bone defect.

The Emerging Biomaterial Categories

A 2026 review of biomaterials for osteomyelitis frames the field's direction precisely: material design now targets anti-infection and tissue regeneration as one engineering problem, not two (Yin et al., 2026, PMID 42609352). Four categories matter for clinicians evaluating products.

Antibiotic-loaded degradable bone graft substitutes. Calcium sulfate and calcium phosphate-based substitutes loaded with vancomycin, tobramycin, or gentamicin fill the debrided defect while eluting antibiotic locally, then degrade — eliminating the removal surgery PMMA requires (Jiang et al., 2024, PMID 38600942). A systematic review of clinically available antimicrobial bone graft substitutes in osteomyelitis treatment reached the same practical conclusion: these materials combine dead-space management with local drug delivery (van Vugt et al., 2016, PMID 26904683). A completed ClinicalTrials.gov study of antimicrobial synthetic bone grafts (NCT03945864) reflects the same product category moving through formal clinical evaluation. Release kinetics are tunable — polymer coatings can smooth and extend elution from composite void fillers (Brooks et al., 2014, PMID 24376164) — which matters when selecting a product for a high-burden defect. Bioactive glass S53P4. S53P4 is a borosilicate glass with intrinsic antibacterial activity driven by its alkaline pH and ion release, so it does not require a loaded antibiotic. It has been reported in diabetic foot osteomyelitis case series (De Giglio et al., 2018, PMID 29709419), compared against autologous bone graft for filling defects in chronic osteomyelitis and infected non-unions (Steinhausen et al., 2021, PMID 34084694), and summarized in a 2025 systematic review and meta-analysis (Nguyen et al., 2025, PMID 40424253). A randomized controlled trial of S53P4 in diabetic foot osteomyelitis of the forefoot is currently recruiting (NCT06388603). Immune-modulating and precision materials. The next frontier is biomaterials that actively steer the host response — engineered materials that remodel macrophage polarization, shifting the pro-inflammatory M1 phenotype toward the pro-reparative M2 state as a sequential strategy in bone infection treatment (Shi et al., 2025, PMID 41290567). Precision biomaterial designs for osteolytic diseases extend the same logic to bone loss from infection (Xue et al., 2026, PMID 42444440). These are largely preclinical or early clinical, but they define the trajectory: implants that fight infection while recruiting the cells that rebuild bone.

Comparison: Anti-Infective Biomaterials vs Debridement + Biologic Grafting

| Modality | Anti-infective mechanism | Bone-regeneration role | Typical staging | Evidence level | |---|---|---|---|---| | Antibiotic-loaded degradable bone graft substitute | Local antibiotic elution from degradable carrier | Osteoconductive void filler; no removal surgery | Single-stage fill after debridement | Case series; systematic review (PMID 26904683; PMID 38600942) | | Bioactive glass S53P4 | Intrinsic antibacterial (alkaline pH, ion release) | Osteostimulative bonding to bone | Single-stage; also used inside induced membrane | Case series; meta-analysis (PMID 29709419; PMID 40424253); RCT recruiting (NCT06388603) | | PMMA beads / spacer | High-dose local elution | None — inert spacer; requires removal | Two-stage (removal at second operation) | Long-standing standard (PMID 28837368) | | Biologic soft-tissue allograft (e.g., amniotic membrane) | No direct antimicrobial payload; limited endogenous antimicrobial peptides | Not osteoconductive; supports soft-tissue closure and inflammation control | After infection control, as coverage layer | RCTs in chronic wounds (not osteomyelitis) | | Autologous bone graft | None | Gold-standard osteogenesis and osteoinduction | Delayed reconstruction stage | Standard; S53P4 comparator (PMID 34084694) |

Protocol Implications for Wound-Care and Orthopedic Teams

Single-stage surgery is becoming defensible in selected patients. A protocolized pathway for diabetic foot osteomyelitis that includes antibiotic-loaded bone graft substitute use at the definitive operation has been published — debridement and reconstruction collapsed into one stage when resection is adequate (Chow et al., 2024, PMID 38760999). That changes patient flow: fewer operations, fewer anesthetic events, shorter time to weight-bearing decisions. Material selection should follow the defect, not the brochure. Small, contained cavities after adequate resection are candidates for degradable antibiotic substitutes or S53P4. Large segmental defects at high infection risk may warrant the induced membrane technique — and S53P4 has been used inside the induced membrane itself (Aurégan et al., 2022, PMID 35871084), merging the anti-infective and reconstructive stages. Culture data precede material choice. Because these products differ in elution kinetics and intrinsic activity, tissue culture and susceptibilities should be finalized before selecting a substitute; loading a vancomycin-eluting filler against a resistant gram-negative is a protocol failure, not a product failure. Imaging, documentation, and reimbursement follow. Synthetic substitutes have distinct radiographic and degradation profiles versus autograft, so follow-up imaging may need adjustment, and records should capture material identity, lot, and elution expectations. Reimbursement varies by product, site of service, and payer — verify coverage before adding a device to a value-analysis committee formulary.

When a Biologic Allograft Is Still the Right Call

The anti-infective biomaterials do not eliminate the biologic's role — they reposition it. A biologic soft-tissue allograft is still the right call when:

- The bone defect is controlled but the soft-tissue envelope is compromised. Osteomyelitis often coexists with a chronic wound or sinus tract. Once infection is eradicated and the bone cavity is managed, the overlying defect still needs a biologic scaffold to close — the situation where amniotic membrane and related allografts have their evidence base. - The wound needs inflammation modulation more than structure. Biologics do not fight infection, but applied to a controlled bed they support the healing cascade that synthetic materials cannot fully replace. Autologous platelet-rich plasma, for example, has been reported as an adjunct in chronic calcaneal osteomyelitis with a soft-tissue defect (Wang et al., 2013, PMID 22364433) — a reminder that biologic approaches remain part of the armamentarium at the coverage stage.

The decision rule, in one line: infection burden and structural dead space drive material choice (anti-infective substitute vs staged reconstruction); soft-tissue closure needs drive biologic choice. Placing a biologic allograft over an uncontrolled infected bed is contraindicated regardless of product.

FAQ

Can a biologic allograft treat osteomyelitis? No. Amniotic membrane and related HCT/Ps are soft-tissue scaffolds without structural strength or a meaningful anti-infective payload. They support closure of the wound over a controlled defect; they do not eradicate bone infection or fill bone defects. What is S53P4 bioactive glass? A bioactive borosilicate glass with intrinsic antibacterial activity that also bonds to bone. It is CE-marked and widely used in Europe for osteomyelitis and infected non-unions; a randomized trial in diabetic foot osteomyelitis is recruiting (NCT06388603). Verify US clearance status locally. Antibiotic bone graft substitutes vs PMMA beads — what's the difference? Both deliver local antibiotic, but degradable substitutes fill the defect and resorb, avoiding the second surgery that PMMA bead/spacer removal requires. PMMA remains the standard when staged reconstruction is planned. When can osteomyelitis be treated in one operation? When resection is adequate and the remaining dead space is manageable — protocolized single-stage pathways using antibiotic-loaded bone graft substitutes have been described (PMID 38760999). Large or high-risk defects still warrant staged reconstruction, often with the induced membrane technique.

References

1. Yin SJ, et al. Emerging biomaterials for osteomyelitis treatment: from material design to anti-infection and tissue regeneration. Front Cell Dev Biol. 2026. PMID: 42609352. 2. Lipsky BA, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-e173. PMID: 22619242. 3. Ford CA, et al. Advances in the local and targeted delivery of anti-infective agents for management of osteomyelitis. Expert Rev Anti Infect Ther. 2017. PMID: 28837368. 4. Fung B, et al. The induced membrane technique for the management of long bone defects. Bone Joint J. 2020. PMID: 33249891. 5. Gariani K, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial. Clin Infect Dis. 2021. PMID: 33242083. 6. Jiang C, et al. Current application and future perspectives of antimicrobial degradable bone substitutes for chronic osteomyelitis. Front Bioeng Biotechnol. 2024. PMID: 38600942. 7. van Vugt TA, et al. Clinical application of antimicrobial bone graft substitute in osteomyelitis treatment: a systematic review. Biomed Res Int. 2016. PMID: 26904683. 8. Brooks BD, et al. Molded polymer-coated composite bone void filler improves tobramycin controlled release kinetics. J Biomed Mater Res B Appl Biomater. 2014. PMID: 24376164. 9. De Giglio R, et al. Bioactive glass S53P4: a new opportunity for the treatment in the diabetic foot osteomyelitis. Eur J Intern Med. 2018. PMID: 29709419. 10. Steinhausen E, et al. Bioactive glass S53P4 vs. autologous bone graft for filling defects in patients with chronic osteomyelitis and infected non-unions — a single center experience. J Bone Jt Infect. 2021. PMID: 34084694. 11. Nguyen AT, et al. Safety and efficacy of S53P4 bioactive glass in osteomyelitis management: a systematic review and meta-analysis. J Biomed Mater Res B Appl Biomater. 2025. PMID: 40424253. 12. NCT06388603. RCT on Bioactive Glass S53P4 in Diabetic Foot Osteomyelitis in the Forefoot (DFORCT). ClinicalTrials.gov. RECRUITING. 13. NCT03945864. Antimicrobial Synthetic Bone Grafts. ClinicalTrials.gov. COMPLETED. 14. Shi X, et al. Biomaterial-mediated macrophage polarization remodeling and sequential regulation: a potential strategy in bone infections treatment. Bone Res. 2025. PMID: 41290567. 15. Xue H, et al. Precision biomaterial therapeutic strategies for osteolytic diseases. J Mater Chem B. 2026. PMID: 42444440. 16. Chow J, et al. Definitive single-stage surgery for treating diabetic foot osteomyelitis: a protocolized pathway including antibiotic bone graft substitute use. ANZ J Surg. 2024. PMID: 38760999. 17. Aurégan JC, et al. Utilisation of bioactive glass S53P4 inside an induced membrane for severe bone defect with high risk of infection: a multi-center preliminary experience. Injury. 2022. PMID: 35871084. 18. Wang HF, et al. Chronic calcaneal osteomyelitis associated with soft-tissue defect could be successfully treated with platelet-rich plasma: a case report. Int Wound J. 2013. PMID: 22364433.

Related Resources

- Diabetic Foot Ulcer Treatment Guidelines 2026: Where Biologics Fit - When to Escalate to Biologics in Non-Healing Wounds: A Decision Framework - Optimal Timing of Biologic Application After Debridement - Wound Bed Preparation Before Biologic Application - Antimicrobial Stewardship in Chronic Wound Care - Chronic Wound Biofilm Management: Pre-Graft Debridement and Wound Bed Preparation Protocol